Vaccine

Vaccine: timeline of key events

Jenner was an English physician who helped pioneer the smallpox vaccine based on his hypothesis that the pus in blisters milkmaids received from cowpox protected them from smallpox. To test out his theory in 1796 he inoculated the 8 year old son of his gardener with pus taken from the cowpox blisters of a local milkmaid. While the boy suffered a fever he showed no sign of infection with smallpox. Jenner then injected the child with smallpox material, a common method of immunisation at the time, known as variolation. Again he showed no sign of infection. Following this, Jenner tested the same technique in 23 further people. Based on his success, in 1840 the British government outlawed variolation and provided Jenner's method for free to prevent smallpox. Jenner's work laid the foundation for immunisation as a method for preventing disease and for contemporary discoveries in immunology. 1749-05-17T00:00:00+0000Jenner was an English physician who helped pioneer the smallpox vaccine based on his hypothesis that the pus in blisters milkmaids received from cowpox protected them from smallpox. To test out his theory in 1796 he inoculated the 8 year old son of his gardener with pus taken from the cowpox blisters of a local milkmaid. While the boy suffered a fever he showed now sign of infection with smallpox. Jenner then injected the child with smallpox material, a common method of immunisation at the time, known as variolation. Again he showed no sign of infection. Jenner then tested out the same technique in 23 further people. Based on his success, in 1840 the British government decided to outlaw variolation and instead provide Jenner's method for free to prevent smallpox. Jenner's work laid the foundation for immunisation as a method for preventing disease and for contemporary discoveries in immunology. 1823-01-26T00:00:00+0000Nicolle was a French bacteriologist who won the Nobel Prize in Medicine in 1903 for identifying lice as the transmission vector for epidemic typhus and by working how tick fever is transmitted. He also helped discover the parasite responsible for toxoplasmosis, a common infection that is usually harmless but can cause serious problems in some people. Nicolle also developed a vaccine for Malta fever, a disease now called brucellosis. 1866-09-21T00:00:00+0000Louis Pasteur develops an attenuated chicken cholera vaccine1879-01-01T00:00:00+0000Louis Pasteur successfully tested his rabies vaccine on a nine year old boy who had been bitten by a rabid dog.1885-07-06T00:00:00+0000Goodpasture developed a method of culturing viruses in chicken embryos and fertilized chicken eggs. Before this viruses were grown in living tissues which could be contaminated by bacteria. Goodpasture's method laid the foundation for the development of vaccines for smallpox, yellow fever, typhus and chicken pox.1886-10-17T00:00:00+0000Pasteur was a French chemist and microbiologist who is best known for inventing a sterilisation method for slowing down the development of microbes in milk and wine, a process now called pasteurisation. He also made significant breakthroughs in understanding the causes and prevention of bacterial diseases. His work was instrumental in helping to reduce the mortality rate from puerperal fever, a major cause of death for women in childbirth in the 19th century. Pasteur also pioneered the first rabies vaccine.1895-09-28T00:00:00+0000Enders shared the 1954 Nobel Prize for helping to develop a technique to grow the poliomyeltitis virus in various types of tissue culture. This he achieved with colleagues Thomas Weller and Fredric Robbins in 1949. Their technique paved the way for Jonas Salk's development of a vaccine against polio. Enders is also renowned for having helped pioneer the first measles vaccine. 1897-02-10T00:00:00+0000Wyckoff was a major pioneer of x-ray crystallography of bacteria. He helped develop a high-speed centrifuge for segregating microscopic and submicroscopic material to determine the sizes and molecular weights of small particles. In addition he purified the virus that causes equine encephalomyelitis which laid the foundation for the development of a vaccine to combat an epidemic of the disease in horses. His work in this field enabled him to create a vaccine against epidemic typhus for use in World War II. 1897-08-09T00:00:00+0000Theiler was a physician who specialised in infectious diseases. He is best known for helping to show that yellow fever is caused by a virus and his development of a safe and effective vaccine against the disease. This work he did in the 1930s while based at the International Health Division of the Rockefeller Foundation. His first vaccine was used by the French government to protect the residents of French territories in Western Africa. The second, an improved version that was launched in Brazil in 1938. Over 400 million doses of this vaccine was given out to people over the next 60 years. Theiler was awarded the Nobel Prize for Medicine in 1951 for his yellow fever vaccine. 1899-01-30T00:00:00+0000Stanley was a biochemist and virologist. In 1935 he managed to crystalise the tobacco virus, the causative agent of plant disease. This was a major breakthrough because prior to this no scientists had succeeded in finding out what viruses were. His work laid the foundation for other scientists, using x-ray diffraction, to work out the precise molecular structures and reproduction process of several viruses. During World War II he managed to purify several of the most common influenza viruses and developed a vaccine that was partly effective. In 1946 he shared the Nobel Prize for Chemistry for the 'preparation of enzymes and virus proteins in a pure form.'1904-08-16T00:00:00+0000Sterne pioneered a vaccine against anthrax in 1935 which effectively wiped out the disease. He used Pasteur's methods to develop the vaccine while based at Onderstepoort Veterinary Research Institute, north of Pretoria, in South Africa. His method remains the mainstay for the production of anthrax vaccines for livestock today. In addition to the vaccine he developed bacterial culture methods for both anthrax and botulism and his work laid the foundation for a number of highly successful veterinary and animal vaccines.1905-06-01T00:00:00+0000A medical researcher and virologist, Salk pioneered the first safe and effective polio vaccine. Introduced in 1955, Salk's vaccine helped curb one of the most frightening public health diseases in the world. Over 1,800,000 school children took part in the trial to test his vaccine. His vaccine used killed vaccine rather than weakened forms of the strain of polio used by Sabin to develop another vaccine against the disease. Salk refused to patent his vaccine and made his technique as widely available as possible. His polio vaccine is now on the World Health Organisation's List of Essential Medicine.1914-10-28T00:00:00+0000Robbins was a paediatrician and virologist who made his name in 1941 by helping to develop a tissue culture technique to grow the polio virus, one of the most feared diseases at the time. The method involved the growth of the virus using a mixture of human embryonic skin and muscle tissue. It provided an important step towards the development of a vaccine against polio. The tissue culture technique also helped scientists discover new respiratory viruses and paved the way to culturing the measles virus to make a vaccine against it. Robbins shared the 1954 Nobel Prize for Medicine for his work.1916-08-25T00:00:00+0000Nicolle was a French bacteriologist who won the Nobel Prize in Medicine in 1903 for identifying lice as the transmission vector for epidemic typhus and by working how tick fever is transmitted. He also helped discover the parasite responsible for toxoplasmosis, a common infection that is usually harmless but can cause serious problems in some people. Nicolle also developed a vaccine for Malta fever, a disease now called brucellosis.1936-02-28T00:00:00+0000The first polio vaccine, developed by Jonas Salk, was tested on children from Arsenal Elementary School in Pittsburg, Pennsylvania. Nearly 2 million children in 44 states were tested. The trial showed the vaccine to be effective. The vaccine radically reduced the number of polio victims around the world.1954-02-23T00:00:00+0000Goodpasture developed a method of culturing viruses in chicken embryos and fertilized chicken eggs. Before this viruses were grown in living tissues which could be contaminated by bacteria. Goodpasture's method laid the foundation for the development of vaccines for smallpox, yellow fever, typhus and chicken pox.1960-09-20T00:00:00+0000Created by Leonard Hayflick and Paul S Moorhead.1962-01-01T00:00:00+0000Developed by Samuel Katz and John F Enders, the vaccine would later be incorporated into the MMR, a combination vaccine against measles, mumps and rubella.1963-01-01T00:00:00+0000The vaccine was made by Maurice Hilleman using material taken from his daughter, Jeryl Lynn, when she suffered measles. The Jeryl strain of the mumps vaccine is still in use today and used in the MMR vaccine.1963-01-01T00:00:00+0000The vaccine, RA27/3 had been developed by a team headed by Stanley Plotkin.1969-01-01T00:00:00+0000Stanley was an American biochemist and virologist. In 1935 he managed to crystalise the tobacco virus, the causative agent of plant disease. This was a major breakthrough because prior to this no scientists had succeeded in finding out what viruses were. His work laid the foundation for other scientists, using x-ray diffraction, to work out the precise molecular structures and reproduction process of several viruses. During World War II he managed to purify several of the most common influenza viruses and developed a vaccine that was partly effective. In 1946 he shared the Nobel Prize for Chemistry for the 'preparation of enzymes and virus proteins in a pure form.' 1971-06-15T00:00:00+0000Theiler was a South African trained physician who specialised in infectious diseases. He is best known for helping to show that yellow fever is caused by a virus and his development of a safe and effective vaccine against the disease. This work he did in the 1930s while based at the International Health Division of the Rockefeller Foundation. His first vaccine was used by the French government to protect the residents of French territories in Western Africa. The second, an improved version that was launched in Brazil in 1938. Over 400 million doses of this vaccine was given out to people over the next 60 years. Theiler was awarded the Nobel Prize for Medicine in 1951 for his yellow fever vaccine. 1972-08-11T00:00:00+00001975-01-01T00:00:00+0000AU Bertland, AA Tytell, GP Lampson, E Buynak, 'Method for purifying hepatitis B antigen'm US Patent US4017360A. The patent was granted 12 April 1977.1975-05-14T00:00:00+0000WJ McAleer, EH Wamuth, 'Process for isolating hepatitis b antigen', US Patent 4024243. The patent was granted 17 May 1977.1975-06-16T00:00:00+0000The study carried out in 12 chimpanzees indicated the vaccine would be safe to test in humans, MR Hilleman, EB Buynak, RR Roehm, AA Tytell, AU Bertland, 'Purified and inactivated hepatitis vaccine: Progress Report', American Journal of Medical Sciences, 279/2 (1975), 401-4.1975-09-01T00:00:00+0000Conducted among 1,083 gay men in New York. Gay men were ten times more likely to get hepatitis B than the normal population. Men injected with the vaccine were found to be 75% less likely to get hepatitis B than those who didn't get the vaccine. The trial was done by Wolf Szmuness at New York Medical Center using the vaccine produced by Hilleman at Merck. 1978-01-01T00:00:00+0000The vaccine was developed by Alfred Prince in partnership with John Vnek. Together they devised easier and less expensive purification steps than those used by Merck. The new vaccine required a tenth of the dose than Merck's vaccine. All these measures helped reduce the cost of the vaccine, which was 50 cents per dose. This compared with $90 to $100 for 3 doses of the Merck plasma vaccine. The low cost vaccine was licensed to Cheil Division of Samsung, Korea, Wuhan Institute in China and the Ministry of Healthy in Burma. 1978-01-01T00:00:00+0000The patent was filed on the basis of work undertaken by Kenneth Murray. 1978-12-22T00:00:00+0000The work, funded by Biogen, was undertaken as part of a project to develop recombinant hepatitis B vaccine. It was published in CJ Burrell, P Mackay, PJ Greenaway, PH Hofsneider, K Murray, 'Expression in Escheria Coli of hepatitis B virus DNA sequences cloned in plasmid pBR322', Nature, 279/5708 (1979), 43-47. 1979-02-01T00:00:00+0000F Galibert, E Mandart, F Fitoussi, P Tiollais, P Charnay, , 'Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature, 281/5733 (1979), 646-50; P. Charnay, C Pourcel, A Louise, A Fritsch, P Tiollais, 'Cloning in Escherichia coli and physical structure of hepatitis B virion DNA', PNAS USA, 76/5 (1979), 2222-26; P Charnay, E Mandart, A Hampe, F Fitoussi, P Tiollais, F Galibert, 'Localization on the viral genome and nucleotide sequence of the gene coding for the two major polypeptides of the hepatitis B surface antigen (HBs Ag)', Nucleic Acids Research, 7/2 (1979), 335-46.1979-05-01T00:00:00+0000The research was funded by Merck with the aim of developing a recombinant vaccine against hepatitis B. It was published in P Valenzuela, P Gray, M Quiroga, J Zaldivar, H M Goodman, WJ Rutter, 'Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen', Nature, 280/5725 (1979), 815e819.1979-08-30T00:00:00+0000The patent was based on the work of Kenneth Murray. It was granted in July 1990 as European Patent (UK) No 0182442. 1979-12-21T00:00:00+0000The vaccine was developed by Stanley Plotkin, Hilary Koprowski and Tadeusz Wiktor at the Wistar Institute1980-01-01T00:00:00+00001980-01-01T00:00:00+0000JC Edman, P Gray, P Valenzuela, LB Rall, WJ Rutter, 'Integration of hepatitis B virus sequences and their expression in a human hepatoma cell', Nature, 286/5772 (1980), 535-38.1980-07-31T00:00:00+00001981-01-01T00:00:00+00001981-07-01T00:00:00+0000The vaccines were made with HBsAg purified from plasma of people with chronic hepatitis B. The vaccines were Hevac B Pasteur - made by Merieux and the Pasteur Institute and Hepatavax made by Maurice Hilleman at Merck.1982-01-01T00:00:00+0000The trial was done with 37 healthy adult volunteers. The vaccine was made using HBsAg cloned in yeast. EM Scolnick, AA McLean, DJ West, WJ McAleer WJ Miller, EB Buynak, 'Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA', JAMA 251/21 (1984), 2812-15. 1984-06-01T00:00:00+00001984-07-01T00:00:00+0000An American microbiologist, Enders shared the 1954 Nobel Prize for helping to develop a technique to grow the poliomyeltitis virus in various types of tissue culture. This he achieved with colleagues Thomas Weller and Fredric Robbins in 1949. Their technique paved the way for Jonas Salk's development of a vaccine against polio. Enders is also renowned for having helped pioneer the first measles vaccine. 1985-09-08T00:00:00+0000The vaccine, Hepatabox, was developed by Green Cross using Prince and Vnek's technique. 1986-01-01T00:00:00+0000The vaccine was first approved in West Germany, in May, and then in the US in July. The vaccine was regarded as a breakthrough because it was made from a genetically engineered sub-particle of the virus. This made it much safer than the original vaccine which used the virus sub-particle sourced from the blood of hepatitis B sufferers. The vaccine heralded a new era for the production of vaccines and is a major weapon against one of the most infectious diseases. 1986-05-01T00:00:00+0000HepataxinB was developed by Cheil Sugar using the technique licensed from Alfred Prince and John Vnek.1986-11-01T00:00:00+00001986-12-01T00:00:00+0000The technology was developed at Merck's plant in Montgomery County, Philadelphia. The deal was initiated by Roy Vagelos, Merck's CEO. The aim was to help China deal with its major hepatitis B problem.1989-01-01T00:00:00+00001989-01-01T00:00:00+00001989-05-01T00:00:00+00001990-01-01T00:00:00+00001993-01-01T00:00:00+00001994-01-01T00:00:00+00001994-01-01T00:00:00+0000Wyckoff was a major pioneer of x-ray crystallography of bacteria. He helped develop a high-speed centrifuge for segregating microscopic and submicroscopic material to determine the sizes and molecular weights of small particles. In addition he purified the virus that causes equine encephalomyelitis which laid the foundation for the development of a vaccine to combat an epidemic of the disease in horses. His work in this field enabled him to create a vaccine against epidemic typhus for use in World War II.1994-11-03T00:00:00+0000Developed by William Wunner at the Wistar Institute1995-01-01T00:00:00+0000A medical researcher and virologist, Salk pioneered the first safe and effective polio vaccine. Introduced in 1955, Salk's vaccine helped curb one of the most frightening public health diseases in the world. Over 1,800,000 school children took part in the trial to test his vaccine. His vaccine used killed vaccine rather than weakened forms of the strain of polio used by Sabin to develop another vaccine against the disease. Salk refused to patent his vaccine and made his technique as widely available as possible. His polio vaccine is now on the World Health Organisation's List of Essential Medicine. 1995-06-23T00:00:00+0000Sterne pioneered a vaccine against anthrax in 1935 which effectively wiped out the disease. He used Pasteur's methods to develop the vaccine while based at Onderstepoort Veterinary Research Institute, north of Pretoria, in South Africa. His method remains the mainstay for the production of anthrax vaccines for livestock today. In addition to the vaccine he developed bacterial culture methods for both anthrax and botulism and his work laid the foundation for a number of highly successful veterinary and animal vaccines. 1997-02-26T00:00:00+00001999-01-01T00:00:00+00002001-01-01T00:00:00+00002001-01-01T00:00:00+0000This included 6 member states that had policies for vaccinating adolescents. Of the 89 member states with historically high prevalences of chronic hepatitis B infection, 64 (72%) had adopted universal infant hepatitis B vaccination.2003-05-01T00:00:00+00002003-05-01T00:00:00+0000Robbins was an American paediatrician and virologist who made his name in 1941 by helping to develop a tissue culture technique to grow the polio virus, one of the most feared diseases at the time. The method involved the growth of the virus using a mixture of human embryonic skin and muscle tissue. It provided an important step towards the development of a vaccine against polio. The tissue culture technique also helped scientists discover new respiratory viruses and paved the way to being able to culture the measles virus to make a vaccine against it. Robbins shared the 1954 Nobel Prize for Medicine for his work. 2003-08-04T00:00:00+0000The vaccine RotaTeq took 25 years to develop. It was developed by Stanley Plotkin, H Fred Clark and Paul Offit.2006-01-01T00:00:00+00002007-01-01T00:00:00+0000Published in 'Nature Medicine', the system deloys glycoprotein D fused with genes from target antigens to increase the immune response. The work was led by Hildegund C.J. Ertl.2008-01-31T00:00:00+0000Vaccine developed by David Weiner together with collaborators at Inovio Pharmaceuticals, Inc., GeneOne Life Science, Inc., National Microbiology Laboratory at the Public Health Agency of Canada, and the University of Pennsylvania.2016-06-23T00:00:00+00002017-08-01T00:00:00+0000World Hepatitis Alliance,' Study shows universal vaccination has wiped out hepatitis B and associated liver cancer in Alaska's young people', MedicalXpress, August 10 2017. The study was carried out by Brian McMahon and colleagues at the Alaska Native Tribal Health Consortium (ANTHC) Hepatitis Program. The results was reported to the World Indigenous Peoples' Conference on Viral Hepatitis in Anchorage, Alaska. 2017-08-08T00:00:00+0000The vaccine was developed by Dynavax2017-11-01T00:00:00+0000
Date Event People Places
17 May 1749Edward Jenner was born in Berkeley, United KingdomJennerBerkeley, United Kingdom
26 Jan 1823Edward Jenner diedJenner 
21 Sep 1866Charles J H Nicolle was born in Rouen, FranceNicolle 
1879Chicken cholera vaccine developedPasteurPasteur Institute
1885First rabies vaccine testedPasteurPasteur Institute
17 Oct 1886Ernest Goodpasture was born Clarksville, TN, USAGoodpastureHarvard University
28 Sep 1895Louis Pasteur diedPasteurPasteur Institute
10 Feb 1897John F Enders was born West Hartford, CT, USAEndersChildren's Hospital Boston
9 Aug 1897Ralph W G Wyckoff was born in Geneva, NY, USAWyckoffRockefeller University, University of Michigan, University of Arizona
30 Jan 1899Max Theiler was born in Pretoria, South AfricaTheilerPretoria, South Africa
16 Aug 1904Wendell M Stanley was born in Ridgeville IN, USAStanleyRockefeller Institute
1 Jun 1905Max Sterne was born in Trieste, AustriaSterneOnderstepoort Veterinary Research Institute
28 Oct 1914Jonas Salk was born in New York City, USASalkUniversity of Pittsburgh
25 Aug 1916Frederick Chapman Robbins was born in Auburn AL, USARobbinsWestern Reserve University
28 Feb 1936Charles J H Nicolle diedNicolle 
23 Feb 1954Salk polio vaccine trial begunSalkUniversity of Pittsburgh
20 Sep 1960Ernest Goodpasture diedGoodpastureHarvard University
1962WI-38 cell line developed - important to development of vaccinesHayflick, MoorheadWistar Institute
1963 - 1963Development of first attentuated measles virus vaccineEnders, Katz 
1963Creation of first vaccine against mumpsHillemanMerck & Co
1969 - 1970First license approved in US and Europe for vaccine against rubella (German measles)PlotkinWistar Institute
15 Jun 1971Wendell M Stanley diedStanleyRockefeller Institute
11 Aug 1972Max Theiler diedTheiler 
1975Pasteur Institute scientists started to develop fractionation method to purify HBsAg from plasma to produce hepatitis B vaccineTiollaisPasteur Institute
14 May 1975Merck filed US patent for technique to purify hepatitis B antigenBertland, Tytell, Lampson, BuynakMerck
16 Jun 1975Merck filed US patent for process to isolate hepatitis B antigenMcAleer, WasmuthMerck
September 1975Merck reported positive results from chimpanzee trials with hepatitis B vaccine containing inactivated HBsAg antigenHilleman, Buynak, Roehm, Tytell, BertlandMerck
1978 - 1980First clinical trials with plasma vaccine against hepatitis BSzmuness, HillemanNew York Medical Center
1978 - 1986Low-cost plasma hepatitis B vaccine developedPrince, VnekNew York Blood Center
December 1978Biogen filed preliminary UK patent for technique to clone hepatitis B DNA and antigensKenneth MurrayBiogen, University of Edinburgh
February 1979University of Edinburgh scientists published the successful isolation and cloning DNA fragments of the hepatitis B virus in Escherichia coliBurrell, Mackay, Greenaway, Hofschneider, K MurrayUniversity of Edinburgh, Microbiological Research Establishment, Biogen
May 1979 - Oct 1979Pasteur Institute scientists reported successful cloning of hepatitis B DNA in Escherichia coliGalibert, Mandart, Fitoussi, Tiollais, Charnay, HampePasteur Institute
30 Aug 1979UCSF scientists announced the successful cloning and expression of HBsAg in Escherichia coliValenzuela, Gray, Quiroga, Zaldivar, Goodman, RutterUniversity of California San Francisco, Merck
21 Dec 1979Biogen applied for European patent to clone fragment of DNA displaying hepatitis B antigen specificityMurrayBiogen
1980US licensed first rabies vaccine for human useKoprowski, Plotkin, WiktorWistar Institute
1980Pasteur Institute filed for US patent for fractionation method to purify HBsAg from plasma to produce hepatitis B vaccineTiollaisPasteur Institute
31 Jul 1980UCSF scientists published method to culture HBsAg antigens in cancer cellsEdman, Gray, Valenzuela, Rall, RutterUniversity of California San Francisco
1981 - 1991US hepatitis B vaccination programme directed towards people identified at high risk 
July 1981UCSF and Merck filed patent to snthesise HBsAg in recombinant yeastRutterUniversity of California San Francisco, Merck
1982First plasma vaccines against hepatitis B licensed for market in US and EuropeHillemanMerieux, Institute Pasteur, Merck
1 Jun 1984Genetically engineered vaccine against hepatitis B reported to have positive trial resultsScolnick, McLean, West, McAleer , Miller, BuynakScolnick, McLean, West, McAleer , Miller, BuynakMerck, University California San Francisco
July 1984Taiwan launched nationwide hepatitis B vaccination programme 
8 Sep 1985John F Enders diedEndersChildren's Hospital Boston
1986Low-cost plasma vaccine against hepatitis B approved in Indonesia 
1986First genetically engineered vaccine against hepatitis B approvedScolnickMerck
November 1986Low-cost plasma hepatitis B vaccine gained approval in South KoreaPrince, VnekCheil Sugar
December 1986Genetically engineered hepatitis B vaccine, Engerix-B, approved in BelgiumSmithKline Biologicals
1989Merck sold hepatitis B vaccination manufacturing technology to Chinese government for $7millionVagelosMerck
January 1989Genetically engineered hepatitis B vaccine, Engerix-B, approved in USSmithKline Biologicals
May 1989Genetically engineered hepatitis B vaccine, GenHevac, approved in FrancePasteur Vaccins
1990Hepatitis B vaccine cost US$3 per dose 
1993Hepatitis B vaccination manufacturing plant opened in Beijing, aided by MerckMerck
1994Ten years after rolling out its nationwide hepatitis B vaccination programme Taiwan reported its children's HBsAg carrier rate had reduced from 10% to less than 1% 
1994Hepatitis B vaccination manufacturing plant opened in Shenzhen, aided by Merck 
3 Nov 1994Ralph W G Wyckoff diedWyckoffUniversity of Michigan, University of Arizona
1995US licensed first wildlife rabies vaccineWistar Institute
23 Jun 1995Jonas Salk diedSalkUniversity of Pittsburgh
26 Feb 1997Max Sterne diedSterneOnderstepoort Veterinary Research Institute
1999Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund (VF) launched programme to support poor countries roll-out hepatitis B vaccination 
2001WHO recorded that 126 (66%) of its 191 member states had universal infant or childhood hepatitis B vaccination programmes 
2001Hepatitis B vaccine cost US$0.30 per dose 
May 2003WHO recorded that 151 (79%) of 192 member states had adopted universal childhood hepatitis B vaccination programmes 
May 2003GAVI/VF reported that 48 (64%) of poor countries eligible for their support had received funding to introduce hepatitits B vaccine 
4 Aug 2003Frederick Chapman Robbins diedRobbinsWestern Reserve University
2006Vaccine approved for preventing rotavirus, a major kiler of children Plotkin, Clark, OffitWistar Institute
2007WHO reported that 71 (89%) of its 193 member states had initiated a hepatitis B vaccination programme 
31 Jan 2008New vaccine delivery system unveiled for preventing viral diseasesErtlWistar Institute
23 Jun 2016FDA approved first clinical trial for zika virus vaccineWeinerWistar Institute, University of Pennsylvania, Inovio Pharmaceuticals, GeneOne Life Science, Public Health Agency of Canada
August 2017UK, one of the last countries in Europe, rolled out hepatitis B vaccination programme for infants 
8 Aug 2017Universal hepatitis B vaccination introduced for all newborns in 1980s reported to have wiped out hepatitis B infection and associated liver cancer cases in Alaskan indigenous population 
November 2017FDA approved a two-dose hepatitis B vaccine for use in adults aged 18 and overDynavax

17 May 1749

Edward Jenner was born in Berkeley, United Kingdom

26 Jan 1823

Edward Jenner died

21 Sep 1866

Charles J H Nicolle was born in Rouen, France

1879

Chicken cholera vaccine developed

1885

First rabies vaccine tested

17 Oct 1886

Ernest Goodpasture was born Clarksville, TN, USA

28 Sep 1895

Louis Pasteur died

10 Feb 1897

John F Enders was born West Hartford, CT, USA

9 Aug 1897

Ralph W G Wyckoff was born in Geneva, NY, USA

30 Jan 1899

Max Theiler was born in Pretoria, South Africa

16 Aug 1904

Wendell M Stanley was born in Ridgeville IN, USA

1 Jun 1905

Max Sterne was born in Trieste, Austria

28 Oct 1914

Jonas Salk was born in New York City, USA

25 Aug 1916

Frederick Chapman Robbins was born in Auburn AL, USA

28 Feb 1936

Charles J H Nicolle died

23 Feb 1954

Salk polio vaccine trial begun

20 Sep 1960

Ernest Goodpasture died

1962

WI-38 cell line developed - important to development of vaccines

1963 - 1963

Development of first attentuated measles virus vaccine

1963

Creation of first vaccine against mumps

1969 - 1970

First license approved in US and Europe for vaccine against rubella (German measles)

15 Jun 1971

Wendell M Stanley died

11 Aug 1972

Max Theiler died

1975

Pasteur Institute scientists started to develop fractionation method to purify HBsAg from plasma to produce hepatitis B vaccine

14 May 1975

Merck filed US patent for technique to purify hepatitis B antigen

16 Jun 1975

Merck filed US patent for process to isolate hepatitis B antigen

Sep 1975

Merck reported positive results from chimpanzee trials with hepatitis B vaccine containing inactivated HBsAg antigen

1978 - 1980

First clinical trials with plasma vaccine against hepatitis B

1978 - 1986

Low-cost plasma hepatitis B vaccine developed

Dec 1978

Biogen filed preliminary UK patent for technique to clone hepatitis B DNA and antigens

Feb 1979

University of Edinburgh scientists published the successful isolation and cloning DNA fragments of the hepatitis B virus in Escherichia coli

May 1979 - Oct 1979

Pasteur Institute scientists reported successful cloning of hepatitis B DNA in Escherichia coli

30 Aug 1979

UCSF scientists announced the successful cloning and expression of HBsAg in Escherichia coli

21 Dec 1979

Biogen applied for European patent to clone fragment of DNA displaying hepatitis B antigen specificity

1980

US licensed first rabies vaccine for human use

1980

Pasteur Institute filed for US patent for fractionation method to purify HBsAg from plasma to produce hepatitis B vaccine

31 Jul 1980

UCSF scientists published method to culture HBsAg antigens in cancer cells

1981 - 1991

US hepatitis B vaccination programme directed towards people identified at high risk

Jul 1981

UCSF and Merck filed patent to snthesise HBsAg in recombinant yeast

1982

First plasma vaccines against hepatitis B licensed for market in US and Europe

1 Jun 1984

Genetically engineered vaccine against hepatitis B reported to have positive trial results

Jul 1984

Taiwan launched nationwide hepatitis B vaccination programme

8 Sep 1985

John F Enders died

1986

Low-cost plasma vaccine against hepatitis B approved in Indonesia

1986

First genetically engineered vaccine against hepatitis B approved

Nov 1986

Low-cost plasma hepatitis B vaccine gained approval in South Korea

Dec 1986

Genetically engineered hepatitis B vaccine, Engerix-B, approved in Belgium

1989

Merck sold hepatitis B vaccination manufacturing technology to Chinese government for $7million

Jan 1989

Genetically engineered hepatitis B vaccine, Engerix-B, approved in US

May 1989

Genetically engineered hepatitis B vaccine, GenHevac, approved in France

1990

Hepatitis B vaccine cost US$3 per dose

1993

Hepatitis B vaccination manufacturing plant opened in Beijing, aided by Merck

1994

Ten years after rolling out its nationwide hepatitis B vaccination programme Taiwan reported its children's HBsAg carrier rate had reduced from 10% to less than 1%

1994

Hepatitis B vaccination manufacturing plant opened in Shenzhen, aided by Merck

3 Nov 1994

Ralph W G Wyckoff died

1995

US licensed first wildlife rabies vaccine

23 Jun 1995

Jonas Salk died

26 Feb 1997

Max Sterne died

1999

Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund (VF) launched programme to support poor countries roll-out hepatitis B vaccination

2001

WHO recorded that 126 (66%) of its 191 member states had universal infant or childhood hepatitis B vaccination programmes

2001

Hepatitis B vaccine cost US$0.30 per dose

May 2003

WHO recorded that 151 (79%) of 192 member states had adopted universal childhood hepatitis B vaccination programmes

May 2003

GAVI/VF reported that 48 (64%) of poor countries eligible for their support had received funding to introduce hepatitits B vaccine

4 Aug 2003

Frederick Chapman Robbins died

2006

Vaccine approved for preventing rotavirus, a major kiler of children

2007

WHO reported that 71 (89%) of its 193 member states had initiated a hepatitis B vaccination programme

31 Jan 2008

New vaccine delivery system unveiled for preventing viral diseases

23 Jun 2016

FDA approved first clinical trial for zika virus vaccine

Aug 2017

UK, one of the last countries in Europe, rolled out hepatitis B vaccination programme for infants

8 Aug 2017

Universal hepatitis B vaccination introduced for all newborns in 1980s reported to have wiped out hepatitis B infection and associated liver cancer cases in Alaskan indigenous population

Nov 2017

FDA approved a two-dose hepatitis B vaccine for use in adults aged 18 and over